23andme Holding CO

The U.S. Bankruptcy Court has confirmed Chrome Holding Co.'s Chapter 11 plan, leading to the cancellation of all outstanding common stock and the establishment of a Plan Administration Trust for creditor distributions.

Chrome Holding Co. has filed its Third Amended Joint Plan under Chapter 11, outlining asset sales and settlement agreements for data breach claims, with a confirmation hearing set for November 19, 2025.

Chrome Holding Co. (formerly 23andMe Holding Co.) filed its September 2025 monthly operating report, detailing financial status and ongoing Chapter 11 proceedings, including asset sales and plan confirmation efforts.

Chrome Holding Co. (formerly 23andMe Holding Co.) filed its August 2025 monthly operating report, detailing financial activities and ongoing Chapter 11 proceedings, including asset sales and a significant net loss.

Chrome Holding Co. (formerly 23andMe Holding Co.) has filed its Second Amended Joint Plan of Reorganization and Disclosure Statement in its Chapter 11 bankruptcy proceedings, detailing asset sales and settlement of massive data breach claims.

Chrome Holding Co. (formerly 23andMe Holding Co.) filed monthly operating reports detailing its Chapter 11 bankruptcy progress, including a significant asset sale and a return to positive equity.

23andMe Holding Co. reports significant revenue decline and ongoing losses, confirming a wind-down of operations following the sale of most assets to a related party.

23andMe reports a mixed Q3 with revenue increase driven by a GSK agreement, but expresses substantial doubt about its ability to continue as a going concern.

23andMe's Q2 2025 results show a decrease in revenue and a net loss, alongside strategic changes including a reverse stock split and the closure of its Therapeutics business, raising concerns about its ability to continue as a going concern.

23andMe's first quarter results show a significant revenue decrease year-over-year, alongside ongoing strategic review and a preliminary acquisition proposal.

23andMe's Q3 2024 results reveal a significant net loss, driven by a goodwill impairment charge and decreased revenue, alongside ongoing efforts to address a cyber security incident and Nasdaq listing compliance.

23andMe Holding Co. filed an amended annual report to include executive compensation and corporate governance details, confirming its delisting from Nasdaq and ongoing Chapter 11 bankruptcy proceedings.

23andMe Holding Co. has filed for Chapter 11 bankruptcy, delisted from Nasdaq, and is in the process of selling substantially all of its assets to Regeneron Pharmaceuticals, Inc. for $256 million, with a higher competing bid of $305 million from an affiliate of its co-founder.

23andMe Holding Co. released its fiscal year 2024 results, highlighting a decrease in revenue, a significant goodwill impairment, and ongoing efforts to streamline operations and focus on strategic growth areas.

Chrome Holding Co.'s CEO, CFO, and CAO, Joseph Selsavage, reported the disposition of 5,232 shares of Class A Common Stock.

Anne Wojcicki, a Director and 10% owner of 23andMe Holding Co., converted 4,931,692 shares of Class B Common Stock into Class A Common Stock on June 9, 2025.

Joseph Selsavage, Interim CEO, CFO, and CAO of 23andMe Holding Co., disposed of shares to satisfy tax withholding obligations related to equity awards.

Joseph Selsavage, CFO of 23andMe Holding Co., disposed of 5,654 shares of Class A Common Stock on February 20, 2025, to cover tax obligations.

23andMe's Chief Financial Officer, Joseph Selsavage, disposed of 5,279 shares of Class A Common Stock to cover tax obligations.

Richard Scheller, a director at 23andMe Holding Co., filed a Form 4 disclosing the acquisition and disposition of Class A Common Stock on August 26, 2024.

23andMe Holding Co. has filed a definitive proxy statement with the SEC.

23andMe is asking stockholders to approve a reverse stock split to boost its share price and maintain its Nasdaq listing.

23andMe Holding Co., currently undergoing Chapter 11 bankruptcy, has agreed to sell substantially all of its assets, including its genetic testing and Lemonaid businesses, to TTAM Research Institute, an affiliate of CEO Anne Wojcicki, for $302.5 million, pending Bankruptcy Court approval.

Activist investors Zentree Investments Limited and Richard Magides have disclosed an 18.2% beneficial ownership in 23andMe Holding Co., advocating for minority shareholder rights, prudent cost management, and equal treatment for Class A and Class B shares.

Zentree Investments Limited and Richard Magides have disclosed a 16.0% beneficial ownership stake in 23andMe Holding Co., signaling an activist intent to advocate for minority shareholder rights, improved cost management, and equal share class rights.

Activist investors Richard Magides and Zentree Investments Limited have disclosed a 13.0% beneficial ownership stake in 23andMe Holding Co., signaling an intent to advocate for minority shareholder rights, prudent cost management, and equal voting rights for all share classes.

Anne Wojcicki, CEO of 23andMe Holding Co., has submitted an updated proposal to acquire all outstanding shares not owned by her and affiliates, maintaining the total consideration of up to $2.94 per share while offering new financing and committing to significant operating expense reductions to avoid bankruptcy.

23andMe Holding Co-founder Anne Wojcicki has submitted a revised non-binding proposal to acquire all outstanding shares not owned by her and affiliates for up to $2.94 per share, including upfront cash and contingent value rights, aiming to take the company private to avoid bankruptcy.

Farallon Capital and its affiliated entities have filed a Schedule 13G, revealing a collective beneficial ownership of 6.2% of 23andMe Holding Co.'s Class A Common Stock, indicating a passive investment.

Zentree Investments Limited and Richard Magides have reported a combined 10.0% beneficial ownership stake in 23andMe Holding Co.'s Class A Common Stock, indicating a passive investment.

Zentree Investments Limited and Richard Magides have reported a combined beneficial ownership of 8.4% of 23andMe Holding Co.'s Class A Common Stock as of December 31, 2024.